3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 2
1
Status
Withdrawn
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
10
Lung Neoplasms
6
Small Cell Lung Carcinoma
2
Neoplasms
2
Triple Negative Breast Neoplasms
1
Thymoma
1
Small Cell Lung Cancer Limited Stage
1
Mesothelioma, Malignant
1
Melanoma
1
Limited Stage Small Cell Lung Cancer
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Interventions
pembrolizumab
61
Carboplatin
44
Pemetrexed
31
Paclitaxel
31
Docetaxel
31
Cisplatin
27
Gemcitabine
24
Nivolumab
23
Erlotinib Hydrochloride
21
Bevacizumab
18
Ipilimumab
11
osimertinib
10
Drug Therapy
10
atezolizumab
9
Radiosurgery
9
Cyclophosphamide
9
Cetuximab
9
Blood Specimen Collection
9
durvalumab
8
cemiplimab
8
Radiotherapy
8
budigalimab
7
Fluorouracil
7
Dexamethasone
7
trametinib
6
fludarabine
6
dostarlimab
6
avelumab
6
Taxes
6
130-nm albumin-bound paclitaxel
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Neoplasms
×
Radiation Dose Hypofractionation
×
Thoracic
×
Clear all
NCT02947113
2017-11-30
HYPOLAN
The Netherlands Cancer Institute
Phase 2
Withdrawn
NCT01936961
2017-06-27
I-CREST
Western Regional Medical Center
Phase NA
Withdrawn